Can Roche Holding Challenge Eli Lilly, Novo Nordisk in Weight Loss Market?

  • 📰 Investingcom
  • ⏱ Reading Time:
  • 45 sec. here
  • 4 min. at publisher
  • 📊 Quality Score:
  • News: 28%
  • Publisher: 53%

Eli Lilly And Company News

Novo Nordisk A/S,Roche Holding Ltd ADR

Stocks Analysis by MarketBeat.com (Leo Miller) covering: Eli Lilly and Company, Novo Nordisk A/S, Roche Holding Ltd ADR. Read MarketBeat.com (Leo Miller)'s latest article on Investing.com

An analyst at Deutsche Bank recently referenced a drug as a threat to Eli Lilly's competing treatment.Over the last couple of years, one of the biggest stories in the stock market has been around pharmaceutical companies that are thriving due to the proliferation of their weight loss drug treatments.

Due to this, many are paying close attention to which company will be next to develop a new and hopefully improved weight-loss drug that can lead to similar stock price success.One interesting distinction in the weight loss drug landscape is that of injectable drugs versus oral drugs. Lilly and Novo currently deliver their drugs Zepbound and Wevogy, via self-injections. However, research at these and other firms is working to develop weight loss treatments as a once-daily oral pill.

These results are encouraging but also lead to significant questions. First, the company only released data after four weeks. This is a very short time frame; data for orforglipron is available for up to 36 weeks. However, it is from a Phase 2 trial, so that is to be expected. The CT-988 results were reportedly only based on the testing from six patients, a very low sample size.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 450. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly and Company announce $4.5 billion investment in Lebanon LEAP district facilityOn Wednesday, Eli Lilly and Company announced a $4.5 billion investment into a new 'first of its kind' facility in Lebanon's LEAP district.
Source: wrtv - 🏆 598. / 51 Read more »